Biotech "Tweets of the Week" for January 26-30, 2015Go Pats!
|
|
$BCLI "exceptional preclinical results" lol!!!
— Juan P. Serrate, DVM (@JPZaragoza1) January 26, 2015
So $juno no longer $aapl of biotechs lol
— Pawcio (@pawcio2009) January 26, 2015
$ICPT trying to break out of range once again last 2 times stalled maybe third time the charm
— Dan Rosenblum (@sharkbiotech) January 26, 2015
Alas, cancer cures with 0% risk are still science fiction
— Stan D'Andrea, Ph.D. (@stanleydandrea) January 26, 2015
$REGN $SNY were supposed to be at least 1Q behind $AMGN, now they leapfrog ahead! Smart move for buying $BMRN's priority review voucher!
— Andy Biotech (@AndyBiotech) January 26, 2015
Paid the HOD of day on $RMTI 13 Feb puts at $2. Still gonna bank. As the saying goes "The trend is your pal"
— DeadCatBill (@getbillasap) January 26, 2015
$RMTI just got approval on something that will never be used probably. Good job!
— Ray Man (@RmanAudio) January 26, 2015
$GILD up 21 points from the $ESRX panic bottom
— Dan Rosenblum (@sharkbiotech) January 26, 2015
U.S. TO OVERHAUL MEDICARE PAYMENTS TO DOCTORS, HOSPITALS
— zach (@zbiotech) January 26, 2015
Great day in Bioland.
— BioBounce.com (@BioBounce) January 26, 2015
Exclusive! $BIIB and $GOOG X Life Sciences are partnering to study drivers of multiple sclerosis. Story on @business.
— Caroline Chen (@CarolineYLChen) January 27, 2015
Winter Storm $JUNO hits and all CARs have to get off the road. Go figure. Question is whether the hype delivers expected outcomes
— Bruce Booth (@LifeSciVC) January 27, 2015
$ZGNX Expecting to see a ramp into Friday's PDUFA, and possible break of the 1.48 near term resistance
— BioBreakout (@BioBreakout) January 27, 2015
@Festo50 I bought $cur $xoma & $enta today. Better to buy when they've been knocked down. R/R just improved. Only starter positions in 1st 2
— Joe (@Drchik23) January 27, 2015
RT @jennmcnary: $SRPT This week is Austin's "week 12" of the 12 weeks add'l safety data requested by @US_FDA -no AEs at all
— Joe (@GantosJ) January 27, 2015
$AMGN Kyprolis $91M (expected $107M)
— Tyler (@TylerHCanalyst) January 27, 2015
Sold 1/2 of my $OTIC position from Fri for ~20% gain. Thanks to @bradloncar and the rest of the biotwitter gang
— Stan D'Andrea, Ph.D. (@stanleydandrea) January 27, 2015
$SRNE data should be late March. 6 weeks for treatment plus short analysis given bioequivalence study. $CELG
— PropThinker (@PropThinker) January 28, 2015
@sharkbiotech New cobi trials in their slide deck.
— David Miller (@AlpineBV_Miller) January 28, 2015
$omer ..past due data update..now an offering..
— M. Richardson (@rhmconsultants) January 28, 2015
Research heads @ $REGN $VRTX $MRK (likely others) receive invitation to White House Fri - expected to discuss Precision Medicine Initiative
— Meg Tirrell (@megtirrell) January 28, 2015
@Emory_R Remember when this first came out how they said their auditor stood by all past financials? You knew that was a joke.
— Brad Loncar (@bradloncar) January 28, 2015
$VRTX 2014 KALYDECO rev $464M
— Bio Stocks™ (@BioStocks) January 28, 2015
$VRTX priorities 2015 1) approval + launch of Kalydeco+VX-809 2) advancing pipeline w/. focus on next gen meds 3) expanding into other areas
— Red Acre Investments (@redacre) January 28, 2015
@biofan1 yes I am long - $MRNS and $SAGE are good plays on neurosteroids for 15
— Alfredo Fontanini (@AF_biotech) January 29, 2015
Tmrw in biotech should be fun. $ONCE IPOs and $ICPT trades post BTD news w 18.75% short float.
— 23aloha (@23aloha) January 29, 2015
— Adam Feuerstein (@adamfeuerstein) January 29, 2015
It's time for $APPY to roll over and die. -99.3% return from 2003 IPO.
— PropThinker (@PropThinker) January 29, 2015
$KBIO $APPY $AEZS Kinda strange how even the old dog food trades never bounced more than a few cents, Markets are changing change with them
— Bio Penny Picks (@pennystocksusa) January 29, 2015
@lomu_j @jq1234t @PRB51 So far Missouri is the only state that has committed. $GILD claims that it's still negotiating w the other 24 states
— Andy Biotech (@AndyBiotech) January 29, 2015
@23aloha It amazes me the diverse group of people who are here.
— Brad Loncar (@bradloncar) January 29, 2015
$XNCR all the way to -6% from +40% this morning. Welcome to biotech.
— PropThinker (@PropThinker) January 29, 2015
$ICPT BTD for OCA in NASH
— zach (@zbiotech) January 29, 2015
Sold my icpt +50%...will revisit
— Randy (@lipscrl) January 29, 2015
You remember those documentaries where they catch the big shark, open it up and find a ton of garbage in its stomach? $VRX is that shark.
— Adam Feuerstein (@adamfeuerstein) January 30, 2015
Glad I don't own $VRX shares, stock could well fall tomorrow in utter shock
— Sally Church (@MaverickNY) January 30, 2015
@TomSilver39 that is just FREAKING UNBELIVABLE Are they that STUPID
— dougheuring (@dougheuringaria) January 30, 2015
$ABBV expects a number of current HCV contract negotiations to wrap up over the next 30 days
— zach (@zbiotech) January 30, 2015
"The biopharma space is a national treasure we have to protect" --@SquawkCNBC hour on Modern Medicine
— Meg Tirrell (@megtirrell) January 30, 2015
"We shouldn't just celebrate innovation - We have to invest in it" #potus #precisionmedicine
— Red Acre Investments (@redacre) January 30, 2015
Today I'm loving the V-pack for some folks with sig renal impairment. Nice to have options. $abbv $gild
— biotechnicality (@biotechnicality) January 30, 2015
The APOCALYPSE is near:
1) $VRX bids for $DNDN
2) @adamfeuerstein somewhat +'ve on $CTIC
http://t.co/UKwwM35Hy9 via @TheStreet
— LifeSciencesMkt (@LifeSciencesMkt) January 30, 2015
@adamfeuerstein @sharkbiotech @MarkSchoenebaum good ... biotech correction/crash is now averted for the time being
— Chet Stedman (@ChetStedman5) January 30, 2015
$CPRX to the moon!
— Shane Blackmon (@shaneblackmon) January 30, 2015
Btw I like $ONCE- def my favorite among gene tx plays. Just pointing out there's no need to rush to buy TODAY as bio IPO history shows
— Vikram Khanna (@VikramKhanna_) January 30, 2015
WRT to 'are we in a bubble', I don't think we are when the President of the United States is profiling the industry as a national priority.
— Brad Loncar (@bradloncar) January 30, 2015
@bradloncar @adamfeuerstein @Sport234a @CT_Morrison Nice demonstration of the current wall of worry.
— David Miller (@AlpineBV_Miller) January 30, 2015
@ahlstrac always have to worry a little when CSO leaves while an important data point is pending. $BLUE
— David Sobek (@dsobek) January 30, 2015
@srqstockpicker @BioRunner59 I have a very complicated opinion on $SGMO but generally like it.
— David Sobek (@dsobek) January 30, 2015
@LauraDeming Yes- Epizyme, Agios, Foundation, Kite, Bluebird, Oncomed even sub-75%ers like Avalanche Juno Kite- full list too long for twtr
— Vikram Khanna (@VikramKhanna_) January 30, 2015
$OTIC - Complete Roundtrip from last week's post offering bounce
— DCam (@dcamtrades) January 30, 2015
I just re-added $IWM puts, so mkt can rocket 3% now. promised myself that I won't sell them so quick this time.
— Chris Ahlstrand (@ahlstrac) January 30, 2015
MT @MistaMista_3: IPOs $SHAK up 118% $ONCE up 119% $SHAK pushed for weeks but gets outperformed!
— Steven Dickman (@cbtadvisors) January 30, 2015
$CMRX stopping participation in clinical trials of brincidofovir for #Ebola, company says, citing declining number of new cases in Liberia
— Meg Tirrell (@megtirrell) January 30, 2015
$ZGNX Receives FDA Approval Of New Formulation Of Zohydro ER
— Bio Stocks™ (@BioStocks) January 31, 2015
$FATE CMO quits. Tired of working in HCT field http://t.co/MaAyAMGgvM
— j l (@lomu_j) January 31, 2015
$BIIB adds 10% yesterday, or $9B to its market cap. For context, that's bigger than the entire amount raised by all the Biotech IPOs in 2014
— Bruce Booth (@LifeSciVC) January 31, 2015
@adamfeuerstein so depressing. Ignorance and anti science runs in both extreme ends of political philosophy.
— Bijan Salehizadeh (@bijans) January 31, 2015
We need a slider for how we choose to spend our taxes. I'd move all my $ to biotech & space exploration away from wars & sports.
— Adam Singer (@AdamSinger) January 31, 2015
Answer: My folks, avid news consumers in Wisc., esp into national politics, never heard a word about Obama's #precisionmedicine push
— Luke Timmerman (@ldtimmerman) January 31, 2015
$ONCE's market cap relative to other gene therapy companies on a fully-diluted basis (my data): pic.twitter.com/JNUn92YOyl
— Brad Loncar (@bradloncar) January 31, 2015
@redacre new CFO, new CEO, new financials. Looks like clearing the deck for the sale. Surprised 2013 restated.
— Emory Redd (@Emory_R) February 1, 2015
At doc with oldest kid for fever, aches. Asked if she's been to Africa or *California*. That was pretty fast (measles is on campus).
— Michelle Fay Cortez (@FayCortez) February 1, 2015